Pregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCA
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-40
SponsorJules Bordet Institute
About this trial
The present study aims to refine the understanding of the prognostic impact of pregnancy after breast cancer in young women harboring germline pathogenic variants in breast cancer susceptibility genes other than BRCA
Eligibility criteria
Qualifiers
Diagnosis of stage I-III invasive breast cancer between January 2000 and December 2025
Age at breast cancer diagnosis ≤40 years
Germline pathogenic variant in at least one of the following breast cancer susceptibility genes other than BRCA: TP53, PALB2, PTEN, CDH1, STK11, CHEK2, ATM, BARD1, RAD51C, or RAD51D
Disqualifiers
Known germline pathogenic variant in breast cancer susceptibility genes without a diagnosis of invasive breast cancer
Diagnosis of ovarian cancer or other malignancies without a prior history of invasive breast cancer
Diagnosis of invasive breast cancer with germline variants of uncertain significance in breast cancer susceptibility genes
De novo stage IV breast cancer
Trial design
Treatments tested in this trial
- Not listed
Trial groups
2,200 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov